There are no big surprises in Alzinova’s Q2’21 interim report. As the company plans to take its vaccine candidate – ALZ-101 – into the clinical stage in Q3'21, we see exciting times ahead.
ANNONS
There are no big surprises in Alzinova’s Q2’21 interim report. As the company plans to take its vaccine candidate – ALZ-101 – into the clinical stage in Q3'21, we see exciting times ahead.